PET/CT imaging and the oligometastatic prostate cancer patient: An opportunity for a curative approach with high-dose radiotherapy?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1267-1269

  Miralbell, Raymond ^a,b   Buchegger, Franz ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Service of Radiation Oncology   (Spain)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11;

BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HEALTH STATUS; HUMAN; LEAN BODY WEIGHT; LONG TERM SURVIVAL; METABOLIC SYNDROME X; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; MALE; METASTASIS; MULTIMODAL IMAGING; PATHOLOGY; PROSTATIC NEOPLASMS;

HUMANS; MALE; MULTIMODAL IMAGING; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903719108     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2793-8     Document Type: Editorial

References (27)

1. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-josef E, Mendelson DS, et al. Initial hormonal management of androgensensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596-605. (Pubitemid 46733088)
2. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, Mcleod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-42. (Pubitemid 28457865)
3. Alibhai SM, Gogov S,Allibhai Z. Long-termside effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60:201-15. (Pubitemid 44709617)
4. SadetskyN, Lubeck DP, Pasta DJ, LatiniDM, Duchane J, Carroll PR. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. BJU Int. 2008;101:691-7. (Pubitemid 351270007)
5. Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fossa SD. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate. 2010;70:1480-9.
6. Da Calais Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55:1269-77.
7. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895-903.
8. Lawton CA,Winter K, Grignon D, PilepichMV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005;23:800-7. (Pubitemid 46224179)
9. Mottet N, Bellmunt J, BollaM, Joniau S,Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572-83.
10. Brogsitter C, Zophel K, Kotzerke J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl MedMol Imaging. 2013;40 Suppl 1:S18-27.
11. Picchio M, Giovannini E, Messa C. The role of PET/computed tomography scan in the management of prostate cancer. Curr Opin Urol. 2011;21:230-6.
12. Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, et al. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:68-78.
13. Harada M, Iida M, Yamaguchi M, Shida K. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol. 1992;324:173-82. (Pubitemid 23007157)
14. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol, Biol, Phys. 2004;58:3-10. (Pubitemid 38010330)
15. Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012;39(6):936 - 43.
16. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvicretroperitoneal lymphadenectomy. Eur Urol. 2007;52:423-9. (Pubitemid 46963456)
17. Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2009;48:1-9.
18. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, TutoloM, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by (11C)choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935-43.
19. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44
20. Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, et al. 11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014. doi:10.1007/S00259-014-2734-6.
21. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622-8.
22. Kahkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434-43.
23. Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867-72.
24. Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist - from mice to men. Theranostics. 2014;4:412-9.
25. Afshar-Oromieh A, Zechmann CM, MalcherA, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Galabelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
26. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a (68)Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887-97.
27. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014. doi:10.1007/S00259-014-2713-y.